Every material Form 8-K Entrada Therapeutics, Inc. has filed with the SEC since August 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Entrada Therapeutics reported third-quarter 2026 results with a net loss of $39.7 million, down from $44.1 million a year earlier, as research and development expenses fell to $32.4 million from $38.4 million. Collaboration revenue dropped to $0.9 million from $1.6 million, and cash, cash equivalents and marketable securities fell to $193.0 million from $295.7 million at December 31, 2025, which the company says extends its cash runway into the fourth quarter of 2027.
Q3 2026 net loss was $39.7 million, compared with $44.1 million in Q3 2025.
Collaboration revenue was $0.9 million, compared with $1.6 million in Q3 2025.
R&D expenses were $32.4 million, compared with $38.4 million; G&A expenses were $10.2 million, compared with $10.3 million.
Cash, cash equivalents and marketable securities were $193.0 million as of September 30, 2026, versus $295.7 million at December 31, 2025, with runway stated into Q4 2027.
Entrada Therapeutics said Cohort 1 of its Phase 1/2 ELEVATE-45-201 study of ENTR-601-45 in Duchenne muscular dystrophy met its primary safety and tolerability objectives at a 5 mg/kg dose. Secondary results showed a 0.10% mean increase in dystrophin production from baseline in treated participants versus a 0.02% mean decrease in placebo, and the company said no observable functional benefit was expected or seen after three doses. The data are early and small, with eight participants in the cohort, and Cohort 2 data at 10 mg/kg are expected in the first half of 2027.
Cohort 1 enrolled eight participants randomized 3:1 to ENTR-601-45 at 5 mg/kg or placebo, dosed on days one, 43 and 85.
Mean dystrophin increase of 0.10% from baseline (n = 6, nominal p = 0.03) versus a 0.02% mean decrease for placebo.
Headache (5 events in 2 participants) was the most common treatment-emergent adverse event; no study discontinuations occurred.
Cohort 2 (10 mg/kg) data are expected in the first half of 2027, with Cohort 3 (up to 15 mg/kg) to follow.
Entrada Therapeutics reported second quarter 2026 results, with a net loss of $42.8 million, slightly narrower than $43.1 million a year earlier. Collaboration revenue fell to $0.9 million from $2.0 million, and cash, cash equivalents and marketable securities dropped to $223.0 million from $295.7 million at December 31, 2025. The company said its cash is sufficient to fund operations into the third quarter of 2027 and listed several clinical data readouts expected between October 2026 and the first half of 2027.
Net loss was $42.8 million, or $1.01 per share, versus $43.1 million, or $1.04 per share, in Q2 2025.
Collaboration revenue was $0.9 million, down from $2.0 million in Q2 2025.
Cash, cash equivalents and marketable securities were $223.0 million on June 30, 2026, versus $295.7 million on December 31, 2025; the company expects them to fund operations into Q3 2027.
ELEVATE-45-201 Cohort 1 data are expected in October 2026, and ELEVATE-44-201 Cohort 1 open-label data by year-end 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Entrada Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →